Ascentage Pharma raises $126m in 1st biotech IPO of 2025

Ascentage raises $126m in first biotech IPO of 2025
Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.
Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual assault, domestic violence charges in LA
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics
Ascentage Pharma sets terms for $149 million US IPO
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange.
Takeda-backed Ascentage Pharma targets $1.8 bln valuation in US IPO
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Ascentage Pharma raises $126M via U.S. IPO (update)
Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.
Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Takeda-backed Ascentage Pharma sets terms for $170M IPO
Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a $170M U.S. initial public offering. Read more here.
Ascentage Pharma ADSs to Begin Trading on Nasdaq
Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
J.P. Morgan and Citigroup are acting as joint book-running managers for the offering.